KRT5 and breast cancer: While the results of combinatorial therapeutic strategies with retinoids in patients with breast cancer have been generally disappointing [165], retinoids have been shown to inhibit the expansion of chemoresistant cytokeratin 5-positive (CK5+) cells through RAR/PR crosstalk [166].